Plus Therapeutics, Inc. (PSTV )

Currency in USD Disclaimer
$0.75 -$0.46 (-38.01%)
Open 03/14/2025
$0.75
$1.1
$0.24
$2.67

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol PSTV
  • Company Plus Therapeutics, Inc.
  • Price $0.75
  • Changes Percentage -38.01
  • Change -0.4599
  • Day Low $0.75
  • Day High $1.1
  • Year High $2.67
  • Year Low $0.24
  • Market Cap $4,422,837
  • Price Avg 50 EMA (D) $1.14
  • Price Avg 200 EMA (D) $1.43
  • Exchange NASDAQ
  • Volume 3,511,085
  • Average Volume 8,632,211
  • Open $1.1
  • Previous Close $1.21
  • EPS -2.37
  • PE -0.32
  • Earnings Announcement 2025-03-13 15:00:00
  • Shares Outstanding $5,896,330

Company brief: PLUS THERAPEUTICS, INC. (PSTV )

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

PSTV Corporation News

D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement

D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement

March 11, 2025 at 3:00 pm ET

accessnewswire.com -- HOUSTON, TX / ACCESS Newswire / March 11, 2025 / On March 4th, Plus Therapeutics, Inc. (Nasdaq:PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with...

Income Statement